A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity

Diana Rasoulouniriana, Nadine Santana-Magal, Amit Gutwillig, Leen Farhat-Younis, Yariv Wine, Corey Saperia, Lior Tal, Haim Gutman, Alexander Tsivian, Ronen Brenner, Eiman Abu Bandora, Nathan E. Reticker-Flynn, Peleg Rider, Yaron Carmi*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

While a high frequency of Th1 cells in tumors is associated with improved cancer prognosis, this benefit has been attributed mainly to support of cytotoxic activity of CD8+ T cells. By attempting to potentiate antibody-driven immunity, we found a remarkable synergy between CD4+ T cells and tumor-binding antibodies. This surprising synergy was mediated by a small subset of tumor-infiltrating CD4+ T cells that express the high-affinity Fcγ receptor for IgG (FcγRI) in both mouse and human patients. These cells efficiently lyse tumor cells coated with antibodies through concomitant crosslinking of their T cell receptor (TCR) and FcγRI. By expressing FcγRI and its signaling chain in conventional CD4+ T cells, we successfully employed this mechanism to treat established solid cancers. Overall, this discovery sheds new light on the biology of this T cell subset, their function during tumor immunity, and the means to utilize their unique killing signals in immunotherapy.

Original languageEnglish
Pages (from-to)4151-4164
Number of pages14
JournalJournal of Clinical Investigation
Volume129
Issue number10
DOIs
StatePublished - 1 Oct 2019

Funding

FundersFunder number
Israel Cancer Association20180041
Israel Science Foundation2262/18
Swiss Bridge Foundation

    Fingerprint

    Dive into the research topics of 'A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity'. Together they form a unique fingerprint.

    Cite this